Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $61.8452W HIGH $87.64
Volume
1.19 M
Value Traded
261.05 M
Short % Float
3.63%
-0.99%Week
-7.75%1 Month
-6.9%3 Month
-19.07%6 Month
-1.57%5 Year
+16.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
30.52 B
EPS (TTM)
-1.74
P/E Ratio
-
Ent. Value
35.74 B
Total Shares
483.40 M
Float Shares
481.57 M
Insiders
0.11%
Institutions
53.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALC Catalyst Timeline
Dated clinical, regulatory and corporate events for Alcon Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alcon Inc.
359Total events
2Upcoming
134Tier-1 (high impact)
2002 to 2026Coverage
Upcoming catalysts 2
TBD
T2Milestone Payment
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 50
▲Product LaunchPost-Market
Initial commercial launch of UNITY M in select markets including U.S. and Japan
▲Other Regulator MilestoneEx-US Regulatory
UNITY M received CE Mark and regulatory approvals in India, Europe, Canada, Japan and the U.S.
▲Partnership / LicenseCorporate
Aravind Alcon Global Centre of Excellence for vitreoretinal surgery training opened in Coimbatore, India
vitreoretinal surgery trainingsource ↗
▲Partnership / LicenseCorporate
Alcon and RxSight announce collaboration to develop adjustable PCIOLs
cataract surgerysource ↗
▲Milestone PaymentCorporate
RxSight receives $60 million upfront payment from Alcon
cataract surgerysource ↗
▲Product LaunchTOTAL30Post-Market
U.S. launch of TOTAL30 Multifocal for Astigmatism
presbyopia with astigmatismsource ↗
▲Product LaunchPRECISION7Post-Market
Canadian launch of PRECISION7 sphere and toric contact lenses
refractive errorsource ↗
▲Product LaunchTOTAL30Post-Market
International launch in limited markets in 2026
presbyopia with astigmatismsource ↗
▲Runway Guidance UpdateCorporate
Updated full-year guidance raised core operating margin and core diluted EPS growth
●Quarterly UpdateCorporate
Aerie full year 2022 net product revenue guidance $130-140 million
▲Partnership / LicenseSimbrinzaApprovedCorporate
Alcon signs agreement to acquire exclusive U.S. commercialization rights to Simbrinza from Novartis
open-angle glaucoma or ocular hypertensionsource ↗
▲Product LaunchPost-Market
U.S. launch of Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops
dry eyesource ↗
◆Oral PresentationPresentation
Launch activities at American Academy of Ophthalmology annual meeting
cataract surgerysource ↗
●Timing GuidancePresentation
Plan to file PMA with FDA for AcrySof IQ ReSTOR Toric IOL
cataract with astigmatismsource ↗
▲Manufacturing MilestoneCMC / Inspection
Expected completion of new pharmaceutical manufacturing plant in Singapore
▲Manufacturing MilestoneCMC / Inspection
New manufacturing facility expected to be fully functional
◆Management ChangeCorporate
Richard Croarkin to step down as CFO, remain until November 30, 2010
▲Product LaunchPost-Market
Launch of Systane BALANCE Lubricant Eye Drops in the United States
dry eye associated with Meibomian Gland Dysfunctionsource ↗
▲Product LaunchTOBRADEXPost-Market
Launch of TobraDex ST suspension in the United States
steroid-responsive inflammatory ocular conditions with bacterial infection or risksource ↗
▲Product LaunchPost-Market
Launch of AcrySof IQ ReSTOR Toric IOL outside the United States
cataract with astigmatismsource ↗
▲Product LaunchPost-Market
Launch of AcrySof IQ ReSTOR Toric lens outside the US
cataract with presbyopia and astigmatismsource ↗
◆Quarterly UpdateCorporate
Extraordinary general meeting of shareholders to vote on conditional election of Novartis-nominated directors
Past FDA Catalysts and PDUFA Decisions
How ALC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-05-28 | Tryptyr (acoltremon) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$842M
Pipeline Value
Not rated
Valuation Signal
5
Drugs Scored
-
rNPV / MCap
Top 29%
Mid Cap(rank 192 of 658)
Percentile Rank
Alcon Inc. carries a moderate pipeline score (44/100), with $996M risk-adjusted pipeline value, led by Apraclonidine in Ocular Hyperemia (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apraclonidine Small moleculeNCT07531043 | Ocular Hyperemia | Phase 3 | NOT YET_RECRUITING | 408 | Feb 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALLEGRETTO WAVE Eye-Q | LASIK surgery | 2009-03-10 | Results demonstrated excellent clinical outcomes on the ALLEGRETTO WAVE Eye-QRead More | Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE Excimer Lasers LASIK chain standardizes with high-end technology based on study results.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zak Kowalczyk MaryOfficer (Vice President) | Option | -667 | $0.00 | 05/17/2011 |
Hedge Fund 13F Activity
Hedge Funds invested in ALC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0.9 % (-57.1 %) | 17.16 M | 255.82 K | -64.95% ( -474.15 K) |
ALC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALC ranks across every disease it competes in
Competitive Position is a premium feature
See how ALC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALC News
ALCIntroducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
Alcon has launched Systane® PRO Preservative-Free in Canada, targeting dry eye symptoms. This new product features a triple-action formula designed to provide relief for up to 12 hours. As a leader in eye care, Alcon continues to innovate in the field with this latest offering.
Read more →ALCAlcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Alcon has officially launched the UNITY® M, a new premium ophthalmic microscope designed to enhance precision and control during eye surgeries. This innovative product aims to improve surgical outcomes and provide surgeons with advanced tools for better performance. The launch reflects Alcon's commitment to advancing ophthalmic technology.
Read more →ALCAlcon Prices EUR 500 Million Senior Notes Offering
Alcon has successfully priced a EUR 500 million senior notes offering. This financial move is expected to bolster the company's financial standing and support its strategic initiatives. The offering reflects investor confidence in Alcon's future prospects.
Read more →ALCNew Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth
Alcon has reported significant growth in the second quarter of 2026, driven by strong commercial execution and successful new product launches. The company's strategic initiatives appear to be yielding positive results, enhancing its market position. This growth reflects Alcon's commitment to innovation and customer satisfaction.
Read more →ALCAravind Eye Care System y Alcon inauguran un centro global para la formación en retina en Coimbatore, India
Aravind Eye Care System and Alcon have inaugurated a global center for retinal training in Coimbatore, India. This center aims to enhance surgical capabilities and improve access to advanced retinal care, addressing a significant shortage of trained specialists. It will initially train around 60 participants annually and utilize scalable virtual education to expand its reach.
Read more →ALCAravind Eye Care System und Alcon eröffnen in Coimbatore, Indien, ein globales Kompetenzzentrum für die Ausbildung im Bereich Netzhautmedizin
Aravind Eye Care System and Alcon have inaugurated the 'Aravind Alcon Global Centre of Excellence' in Coimbatore, India, aimed at enhancing training in vitreoretinal surgery. This center builds on their previous collaboration and addresses the shortage of trained specialists in retinal care. The initiative combines practical surgical training with scalable virtual education to improve healthcare capacity and patient outcomes globally.
Read more →ALCAravind Eye Care System and Alcon Launch Global Centre of Excellence for Retina Training in Coimbatore, India
Aravind Eye Care System and Alcon have launched a Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. This initiative aims to address the shortage of trained retina specialists by providing hands-on surgical training and virtual education. The center will initially train about 60 participants annually and enhance access to quality eye care in underserved regions.
Read more →ALCAlcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine Alcon's optical designs with RxSight's light-adjustable technology, allowing surgeons to fine-tune visual outcomes post-cataract surgery. RxSight will receive an upfront payment of $60 million, with potential additional payments tied to development milestones.
Read more →ALCAlcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
Alcon has launched its UNITY® CS system at the COS 2026 conference, marking a significant advancement in surgical technology. This innovative system is designed to improve surgical outcomes and reflects Alcon's dedication to enhancing surgical practices in Canada. The introduction of this product is expected to set new standards in the field.
Read more →ALCAlcon Announces Results of 2026 Annual General Meeting
Alcon Inc. successfully held its 2026 Annual General Meeting, where shareholders approved all proposed resolutions. Key board members, including Chair F. Michael Ball, were re-elected, and a gross dividend of CHF 0.28 per share was declared. The meeting also included the approval of financial statements and the re-election of statutory auditors.
Read more →ALCAlcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
Alcon has launched the TOTAL30 Multifocal for Astigmatism, the first multifocal toric contact lens featuring Water Gradient Technology. This innovation aims to provide enhanced comfort and clear vision for presbyopic patients with astigmatism. The lenses are now available in the U.S. and will be introduced in select international markets by 2026.
Read more →ALCAlcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
Alcon has announced the launch of PRECISION7, a one-week replacement contact lens featuring the ACTIV-FLO System, in Canada. This innovative lens offers 16 hours of comfort and precise vision, even on day 7. Available from February 2026, it aims to improve patient compliance and experience by providing a more intuitive replacement schedule compared to traditional options.
Read more →ALCAlcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Alcon has received FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, which is indicated for the treatment of the signs and symptoms of dry eye disease.
Read more →ALCCOMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio Builds on Alcon's existing commercial expertise in the estimated $20 bi
MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio Ad hoc announcement pursuant to Art. 53 LR GENEVA, Switzerland and DURHAM, NC August 22, 2022 - Alcon (SIX/NYSE: ALC), the globa
Read more →ALCDocument Alcon Announces Executive Committee Changes Geneva
Alcon Announces Executive Committee Changes Geneva, June 28, 2021 - Alcon (SIX NYSE ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced changes to its Executive Committee of Alcon (ECA). Changes take effect September 1, 2021. Ian Bel
Read more →ALCDocument Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Expands Alcon's existing portfolio and strengthens position in the ophthalmic eye drops market Builds on company's ophthalmic pharm
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Expands Alcon's existing portfolio and strengthens position in the ophthalmic eye drops market Builds on company's ophthalmic pharmaceutical manufacturing expertise Geneva, April 28, 2021 - Alcon (
Read more →ALCAlcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength | Alcon
Alcon announced FDA approval for Pataday Once Daily Relief Extra Strength, the first OTC eye allergy drop providing 24-hour relief. This product expands the Pataday portfolio, enhancing access for allergy sufferers in the U.S.
Read more →ALCGLOSSY PAGES TO ANNUAL REPORT Exhibit 1 | Alcon Annual Report 2019 2 | Alcon Annual Report 2019 Dear Shareholder, In 1945, two pharmacists in Fort Worth, Texas, Robert Alexander and William Conner, started a company that
1 | Alcon Annual Report 2019 2 | Alcon Annual Report 2019 ii | Alcon Annual Report 2019 I am proud of what our team has accomplished following spin-off, particularly in the areas of standing up the new company, accelerating our innovation pipeline to grow revenue, and develop
Read more →ALCAlcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch | Alcon
Alcon announced FDA approval for Pataday eye allergy drops to be sold over the counter, providing prescription-strength relief for 66 million Americans suffering from eye allergies. The product will be available in major retailers starting March 2, coinciding with the spring allergy season.
Read more →ALCCOMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens PanOptix delivers an exceptional combination of near, inte
AUX MEDIAS MEDIENMITTEILUNG AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens August 27, 2019 - Alcon (SIX/NYSE:ALC), the global leader in eye care, today announced the Food and Drug Administration (FDA) approval and its initial commer
Read more →About Alcon Inc.
HeadquartersGeneva
Founded1945
BIOPHARMAWATCH ELITE PLUS
Trade the next ALC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime